Baby Formula NEC Lawsuit: Similac & Enfamil Claims

Federal litigation now consolidates hundreds of claims alleging that cow's-milk-based preterm infant formulas carry a higher risk of necrotizing enterocolitis (NEC) in premature infants than the manufacturers disclosed. Similac and Enfamil are the two brand names named most often. Large headline verdicts have circulated from 2024 to 2026, and reading them correctly matters as much as understanding the underlying allegation.

What Is Necrotizing Enterocolitis (NEC)?

Necrotizing enterocolitis is a serious intestinal disease. It occurs almost exclusively in premature or low-birth-weight infants, most often in the first few weeks of life while a baby is still in the neonatal intensive care unit (NICU). Bacteria invade a weakened section of intestinal tissue. That causes inflammation and, in severe cases, tissue death that can require emergency surgery to remove the affected bowel.

NEC is one of the leading causes of death among premature infants in the NICU. Survivors can face lifelong complications, including short bowel syndrome, developmental delays, and repeated hospitalizations. The disease's exact cause is not fully understood. Neonatologists have long recognized feeding method as one of the strongest known risk factors. Infants fed cow's-milk-based formula, rather than human breast milk or a human-milk-based fortifier, are diagnosed with NEC at meaningfully higher rates in published clinical research.

The Allegation Against Similac and Enfamil

The lawsuits center on Abbott Laboratories' Similac and Reckitt/Mead Johnson's Enfamil cow's-milk-based formula products marketed specifically for premature and low-birth-weight infants. Plaintiffs allege the manufacturers knew, or should have known, that cow's-milk formula carries a substantially elevated NEC risk for preterm infants compared with human milk or human-milk-based alternatives. That knowledge, they say, came from decades of published neonatology research. They also allege the manufacturers marketed and supplied these products to NICUs without adequately warning hospitals, physicians, or parents of that risk.

This is a failure-to-warn theory more than a manufacturing-defect theory: the formula itself is not alleged to be contaminated or built off-specification. The claim is that the known risk profile was not adequately disclosed at the point where a NICU or a parent could weigh it. That is the moment a feeding decision gets made. The decision was often made while the infant was medically fragile. The family, at that point, had little practical ability to shop around.

How the Litigation Is Organized: MDL 3026

The federal cases are consolidated as In re: Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation, MDL No. 3026, in the U.S. District Court for the Northern District of Illinois. The Judicial Panel on Multidistrict Litigation centralized the cases in 2022. They share the same core factual questions about what the manufacturers knew and when. As with the mass tort structure used across the litigation on this site, MDL consolidation coordinates pretrial matters like discovery before one judge. It does not merge the cases into a single lawsuit. Each family's case is still valued on its own facts: the specific product used, the severity of the NEC diagnosis, and the resulting injury.

Beyond the federal MDL, a number of cases have also proceeded in state courts, including Missouri and Illinois. Several of the largest publicly reported verdicts to date have come from state-court juries rather than the federal MDL itself.

Reading the 2024 to 2026 Verdicts and Settlements Correctly

A string of large headline numbers has circulated in NEC litigation coverage since 2024. The single most common misunderstanding in the reporting is treating a jury verdict figure as if it were a guaranteed payout figure for every claimant. It is not, for three separate reasons worth understanding before reading any settlement news. A verdict can be reduced or overturned on appeal. A settlement reached after a verdict is frequently confidential, so the final number paid may not match the number originally reported by the jury. And neither a verdict nor a global settlement fund sets what any individual, unrelated case will recover, because each family's damages are assessed on its own facts.

Publicly reported case activity in this litigation has included a Missouri state-court jury awarding $495 million in a single family's case in 2024. That verdict was later upheld on appeal, then resolved through a confidential settlement reported around August 2026, with the final payment terms not disclosed. Separately, a Chicago jury awarded a combined verdict to four families in a case reported in April 2026. Abbott has also been reported to have reached a broader settlement covering a group of roughly 2,000 infant claimants in August 2026. None of these figures (the $495 million verdict, the undisclosed settlement that followed it, or the broader settlement fund) represents what any other individual family's claim is worth. A new claim is evaluated on its own medical facts. It is never measured against a headline number from someone else's case.

The FDA's Role

Infant formula sold in the United States is regulated by the FDA under the Infant Formula Act. That law sets nutritional and safety requirements but does not require a formula to disclose a comparative NEC-risk warning on its label. The American Academy of Pediatrics and the FDA both recommend human milk as the preferred source of nutrition for preterm infants when available. Hospital feeding guidelines for extremely low-birth-weight infants have shifted over the past decade toward greater use of human-milk-based products in the NICU. Neither the FDA's approval of these formulas for sale nor its general feeding guidance is itself a finding that any manufacturer violated the law. It is background regulatory context that both sides draw on in the litigation.

Who May Have a Claim

Whether a family has a viable claim depends on specific medical and feeding records that only an attorney and a medical record review can evaluate. Attorneys handling these cases generally look for a profile along these lines. This describes the kind of case attorneys assess. It is not a guarantee that any individual case qualifies.

Infant Factors

The infant was born prematurely or at low birth weight and was fed a cow's-milk-based formula, commonly a Similac or Enfamil product marketed for preterm infants, during a NICU stay.

Diagnosis Factors

The infant was diagnosed with NEC, documented in NICU medical records. Imaging or surgical findings confirming the diagnosis and its severity strengthen the record; Bell's staging is commonly referenced in these records.

Outcome Factors

The NEC diagnosis led to a significant medical outcome: surgery, an ostomy, short bowel syndrome, prolonged hospitalization, developmental complications, or death. The severity of the documented outcome is one of the most significant factors attorneys weigh when evaluating a case.

Evidence to Gather

These cases are built almost entirely from hospital and NICU records. Requesting the following early makes an initial attorney consultation far more productive.

Complete NICU feeding records. Records showing exactly which formula product, and which lot or batch if available, the infant was fed and when.

NEC diagnosis and treatment records. Physician notes, imaging, surgical reports, and pathology reports documenting the NEC diagnosis and its severity.

Birth records. Records establishing gestational age and birth weight, since prematurity and low birth weight are central to the litigation's risk theory.

Long-term outcome records. Records of any ongoing treatment, developmental evaluation, or additional surgery tied to the original NEC diagnosis.

Statute of Limitations

Every state sets its own deadline for filing a product liability or personal injury claim, and these deadlines vary. Filing windows in NEC cases have been reported to range roughly from one to six years depending on the state. The exact period, and how it is calculated, differs by jurisdiction. This page does not state a specific number of years that applies to any individual family; an attorney licensed in the relevant state can confirm the actual deadline.

Many states apply a discovery rule, or a separate, longer deadline, when the injured person is a minor. The clock for a child's own claim may not run out at the same time as a parent's related claim. A NEC diagnosis and its long-term consequences may not be fully understood until months or years after a NICU stay. Do not assume a deadline has passed without confirming it with an attorney.

Next Steps

If your child was born prematurely and was fed Similac, Enfamil, or a similar cow's-milk-based formula in the NICU, and was later diagnosed with NEC, gather the records described above. Have them reviewed by an attorney who handles NEC or preterm infant formula litigation. Most attorneys who evaluate these cases offer a free consultation and work on contingency, meaning no fee unless you recover compensation.

See our overview on how to file a lawsuit for a walkthrough of the process. Our mass torts hub covers how NEC litigation relates to other device and drug litigation.

Frequently Asked Questions

What formula brands are involved in the NEC lawsuits?

The litigation centers on Abbott's Similac and Reckitt/Mead Johnson's Enfamil cow's-milk-based formula products marketed for premature and low-birth-weight infants. Other cow's-milk formula brands have been named in some individual cases.

Does the $495 million verdict mean my family would get that much?

No. That figure was one jury's award in one family's individual case, later resolved through a confidential settlement with undisclosed final terms. It does not set, cap, or predict what any other family's case is worth. Every claim is evaluated on its own medical facts.

Is this a class action or a mass tort?

It is organized as multidistrict litigation (MDL), the same mass tort structure used across the other product liability litigation on this site. Each family's case is filed and valued individually, even though pretrial proceedings are coordinated before one federal judge. That is unlike a class action, which resolves everyone's claims together under a single formula.

Do I need proof my baby was fed a specific brand of formula?

Documentation helps significantly. NICU feeding records typically identify the exact product used. If you no longer have copies, your hospital's medical records department can usually provide them on request.

How long do I have to file a baby formula NEC lawsuit?

It depends on your state, and no single deadline applies to everyone. Reported filing windows across these cases have ranged from about one to six years, and some states extend deadlines further when the injured person is a minor. Speak with an attorney promptly to confirm the actual deadline for your family's situation.

What if my child has since passed away from NEC complications?

Some families have pursued wrongful death claims in this litigation. These cases involve additional legal considerations specific to wrongful death law in your state, so speak with an attorney experienced in this litigation as soon as possible.